MiNK - רווח נקי למניה בארבעת הרבעונים האחרונים INKT

The MiNK Therapeutics, Inc. (INKT) price chart illustrates the EPS TTM trend, which currently stands at 25.50. The business relies on partnerships with oncology centers to develop advanced T-cell therapies. The brand's high authority in immuno-oncology is evidenced by the success of iNKT therapy. The company is currently developing a closed clinical trial environment for patients with solid tumors under strict FDA supervision.
INKT (MiNK Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the annual earnings per share (EPS) growth over the last twelve months, allowing for an assessment of business scaling efficiency relative to market capitalization. Analyzing the historical YoY ttm net income per share growth rate helps identify asset undervaluation, which is particularly critical for MiNK Therapeutics, Inc. (INKT) as it implements resource-saving and eco-friendly drug synthesis methods in cell therapy.